These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34942089)

  • 1. Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines.
    Gibani MM
    Lancet Infect Dis; 2022 Apr; 22(4):435-436. PubMed ID: 34942089
    [No Abstract]   [Full Text] [Related]  

  • 2. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 3. A Salmonella typhi Vi conjugate vaccine.
    Koul PA
    N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
    [No Abstract]   [Full Text] [Related]  

  • 4. Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Crump JA; Oo WT
    Lancet; 2021 Aug; 398(10301):643-644. PubMed ID: 34384541
    [No Abstract]   [Full Text] [Related]  

  • 5. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 7. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
    Arya SC
    Vaccine; 1997 Feb; 15(2):244. PubMed ID: 9066045
    [No Abstract]   [Full Text] [Related]  

  • 12. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply.
    Keddy KH; Klugman KP; Robbins JB
    Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329
    [No Abstract]   [Full Text] [Related]  

  • 16. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.
    Lu YJ; Zhang F; Sayeed S; Thompson CM; Szu S; Anderson PW; Malley R
    Vaccine; 2012 May; 30(23):3405-12. PubMed ID: 22465750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines.
    Peng ZH; Pan C; Sun P; Feng EL; Wu J; Zhu L; Peng QZ; Wang HL
    Yi Chuan; 2015 May; 37(5):473-9. PubMed ID: 25998436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.